In addition, our early work also showed that epalrestat, which is used in the targeted treatment of diabetic complications, inhibits the activity of AKR1B1 and controls the NF-κB pathway, thus attenuating the BCSC phenotype and tumor metastasis88 (Figure 2). The gene discussed is NFKB1; the disease is neoplasm.